Marksans Pharma Ltd Share Price
As on 20 December 2025 at 10:48 IST
Marksans Pharma Q1 FY26 Results:
Net profit for the period declined 35% to ₹58 crores in Q1 FY26, from ₹89 crores in Q1 FY25. Total income for the quarter increased 3% year-on-year to ₹626 crores from ₹606 crores.
About Marksans Pharma Ltd
Marksans Pharma Limited is a prominent Indian pharmaceutical company. It is primarily engaged in the manufacturing and marketing of pharmaceutical formulations. The company operates in the pharmaceutical sector, specializing in healthcare and life sciences. It focuses on developing solutions that enhance patient care and overall health outcomes. Its headquarters is in Oshiwara, Andheri (W), Mumbai, Maharashtra. The company was founded in 2000 and offers a wide range of pharmaceutical formulations. These include analgesics, antibiotics, antidiabetics, cardiovascular drugs, and gastrointestinal medications. The company also produces over-the-counter (OTC) products and nutraceuticals. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
-5.62%
Over 6 Months
-27.43%
Over 1 Year
-43.28%
Over 3 Years
196.39%
Marksans Pharma Ltd Summary
Close ₹181.54
Open ₹184
High ₹184.01
Low ₹180.54
Volume 3,84,382
Net Turnover (in Cr) ₹7.02
52Wk High ₹332.40
52Wk Low ₹162
52Wk High / Low
162
332.40
Marksans Pharma Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹8,226.73
EPS (TTM) 5.32
Book Value (BV) 32.99
Div. Yield 0.44 %
P/E (TTM) 34.12
Price/Book Value 5.50
Delivery % 40.27 %
Face Value 1
Key Ratios
PE Ratio 53.58
PB Ratio 7.28
EV to Sales 8.36
PEG Ratio 1.32
ROA 13.45
ROE 14.45
Debt-Equity 0.01
Net Profit Margin 16.03
Operating Profit Margin 23.32
Marksans Pharma Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 2,693.22 | 2,227.83 | 1,911.45 | 1,532.69 | 1,382.88 |
| Total Expenses | 2,189.25 | 1,804.30 | 1,573.80 | 1,285.18 | 1,080.71 |
| Profit Before Tax | 503.97 | 423.53 | 337.65 | 247.51 | 302.16 |
| Profit After Tax | 382.62 | 314.89 | 265.32 | 186.81 | 238.54 |
| Operating Profit After Depreciation | 515.63 | 434.73 | 346.78 | 255.96 | 310.15 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,000.07 | 779.97 | 488.93 | 430.19 | 315.44 |
| Total Non Current Assets | 1,035.51 | 818.46 | 515.09 | 438.90 | 326 |
| Total Current Assets | 2,204.12 | 1,862.49 | 1,675.30 | 1,201.20 | 902.82 |
| Total Assets | 3,239.63 | 2,680.95 | 2,190.39 | 1,640.10 | 1,228.82 |
| Total Shareholder's Fund | 2,466.91 | 2,065.05 | 1,745.16 | 1,202.27 | 886.50 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 206.66 | 230.41 | 237.41 | 99.26 | 178.59 |
| Net Cash Used In Investing Activities | -49.01 | -140.84 | -259.21 | -84.39 | -44.85 |
| Net Cash Used In Financing Activities | -65.15 | -68.73 | 197.83 | 79.51 | -15.29 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,244.21 | 915.35 | 715.69 | 700.54 | 630.70 |
| Total Expenses | 1,000.95 | 743.45 | 583.65 | 566.03 | 506.37 |
| Profit Before Tax | 243.26 | 171.89 | 132.03 | 134.51 | 124.33 |
| Profit After Tax | 188.27 | 133.76 | 102.87 | 103.99 | 98.38 |
| Operating Profit After Depreciation | 244.43 | 172.88 | 135.65 | 138.30 | 129.68 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 383.37 | 271.57 | 143.94 | 135.51 | 129.09 |
| Total Non Current Assets | 673.08 | 568.33 | 431.10 | 375.75 | 369.32 |
| Total Current Assets | 1,082.22 | 947.70 | 913.76 | 589.86 | 371.38 |
| Total Assets | 1,755.30 | 1,516.04 | 1,344.86 | 965.61 | 740.69 |
| Total Shareholder's Fund | 1,383.49 | 1,222.70 | 1,111.32 | 784.67 | 599.72 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 31.02 | 34.05 | 51.73 | 55.97 | 106.92 |
| Net Cash Used In Investing Activities | 17.24 | -114.22 | -194.62 | -128.06 | 8.87 |
| Net Cash Used In Financing Activities | -29.92 | -26.22 | 210.02 | 70.86 | -13.53 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 720.41 | 619.99 | 708.46 | 681.85 | 641.92 |
| Total Expenses | 575.91 | 519.87 | 581.53 | 543.08 | 495.11 |
| Profit Before Tax | 133.33 | 76.59 | 116.09 | 143.26 | 124.60 |
| Profit After Tax | 99.14 | 58.20 | 90.73 | 105.07 | 97.76 |
| Operating Profit after Depreciation | 166.07 | 105.76 | 142.27 | 166.62 | 146.74 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 320.44 | 319.73 | 299.36 | 311.87 | 308.63 |
| Total Expenses | 248.36 | 249.68 | 247.60 | 251.93 | 245.22 |
| Profit Before Tax | 121.49 | 63.57 | 49.91 | 74.73 | 76.34 |
| Profit After Tax | 99.81 | 48.06 | 37.59 | 55.46 | 63.20 |
| Operating Profit after Depreciation | 130.27 | 72.06 | 58.40 | 82.45 | 83.64 |
Marksans Pharma Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 180.05
S2 178.56
S3 176.58
Pivot 182.03
R1 183.52
R2 185.50
R3 186.99
Moving Average
20 SMA 189.08
50 SMA 185.75
100 SMA 185.58
200 SMA 209.62
Marksans Pharma Ltd Corporate Actions
Marksans Pharma Ltd
₹0.8/Share
Announcement Date 01 Aug 2025
Record Date 01 Aug 2025
Div Yield 80%
Marksans Pharma Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,745.35 | ₹4,18,767.93 |
| Divis Laboratories Ltd | ₹6,380.60 | ₹1,69,384.88 |
| Torrent Pharmaceuticals Ltd | ₹3,759.60 | ₹1,27,236.23 |
| Cipla Ltd | ₹1,499.10 | ₹1,21,092.98 |
| Dr Reddys Laboratories Ltd | ₹1,279.60 | ₹1,06,799.30 |
Marksans Pharma Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Kotak Special Opportunites Fund | 2.73% |
| Kotak MNC Fund | 1.77% |
| UTI Multi Cap Fund | 1.42% |
| UTI-Healthcare Fund | 1.26% |
| UTI-Small Cap Fund | 1.09% |
Marksans Pharma Ltd News
Relonchem receives UK MHRA's approval for Cetirizine Dihydrochloride 1 mg/ml Oral Solution
20 Nov 2025, 02:00 pm
Marksans Pharma's arm gets USFDA approval for Loperamide Hydrochloride 2mg tablets
Marksans Pharma announced that its wholly owned subsidiary, Marksans Pharma Inc., has received final approval from the USFDA for its abbreviated new drug application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
19 Nov 2025, 01:30 pm
Marksans Pharma receives USFDA approval for Loperamide Hydrochloride tablets
19 Nov 2025, 11:32 am
Relonchem receives UK MHRA's marketing approval for two products
17 Nov 2025, 11:38 am
Marksans Pharma's Goa unit clears USFDA inspection
10 Nov 2025, 02:08 pm
Marksans Pharma Ltd Stock Analysis
- Annual revenue for Marksans Pharma Ltd increased by 35.93% to ₹1,244.21 crore in FY 2025 from ₹915.35 crore in FY 2024.
- Annual Net Profit for Marksans Pharma Ltd increased by 40.76% to ₹188.27 crore in FY 2025 from ₹133.76 crore in FY 2024.
- Promoter Shareholding in Marksans Pharma Ltd remains unchanged by 0.00% in the most recent quarter, from 43.87% in June 2025 to 43.87% in September 2025.
- Marksans Pharma Ltd delivered a 1-year return of -43.28% compared to the Nifty 50, which provided a return of 6.68% as of the last trading session.
- Marksans Pharma Ltd share price moved up by 1.56% from its previous close of INR ₹181.54. The latest Marksans Pharma Ltd share price is INR ₹184.38.
- Marksans Pharma Ltd share price today has been at a low of 181.71 and a high of 185. Over the past 52 weeks, the Marksans Pharma Ltd share price has seen a low of 162 and a high of 332.40.
About Marksans Pharma Ltd
Marksans Pharma Limited is a prominent Indian pharmaceutical company. It is primarily engaged in the manufacturing and marketing of pharmaceutical formulations. The company produces many finished dosage forms, including tablets, capsules, ointments, and liquids. Marksans Pharma is recognized for its dedication to quality and innovation. The company ensures that all its products comply with international standards.
Marksans Pharma operates in the pharmaceutical sector. Its primary focus is on the healthcare and life sciences industry. The company has been in business since 2000, giving it over two decades of experience in the pharmaceutical field. Its extensive experience has helped the company build a strong presence in domestic markets. Additionally, it has expanded its reach to international markets as well.
The headquarters of Marksans Pharma is located in Mumbai, Maharashtra. This strategic location enhances the company’s operations by providing logistical advantages. It also facilitates easy access to both national and global markets. Mr. Mark Saldanha promotes the company with 43.80% stakes. He plays a crucial role in its strategic direction and growth. A team of professional promoters manages the operations of the company-
Marksans Pharma plays a significant role in the pharmaceutical sector. However, it is not the largest company in terms of market share or market capitalization. Yet, the company has carved out a niche by focusing on quality and innovation. The promoter shareholding in Marksans Pharma is significant, with Mr Mark Saldanha holding a notable stake. This ensures strong governance and strategic oversight for the company.
The registered office and registrar’s office of Marksans Pharma is in Mumbai, Maharashtra. Marksans Pharma Limited is a well-established pharmaceutical company. It is recognized for its diverse product range and unwavering commitment to quality. With strong promoter backing, Marksans Pharma continues to be a key player in the healthcare industry. Its strategic focus on innovation further strengthens its position in the market.
Marksans Pharma’s commitment to quality is one of its most notable impacts. The company ensures that all its products meet stringent international standards. This dedication to quality has earned it certifications from various global regulatory bodies. These include the US FDA, UK MHRA, and Australian TGA.
Innovation is another area where Marksans Pharma has made a significant impact. The company invests heavily in research and development to create improved pharmaceutical formulations. This focus on innovation has led to the development of advanced drug delivery systems and solutions.
The company’s impact extends to its role in making medications more accessible. Marksans Pharma produces a wide range of generic drugs, which are more affordable than their branded counterparts. This affordability makes essential medications accessible to a larger population, particularly in developing countries with limited healthcare resources. Marksans Pharma’s efforts in this area contribute to improving public health and reducing the burden of disease.
The economic impact of Marksans Pharma is also significant. The company employs thousands of people, contributing to economic growth and development. Marksans Pharma’s operations generate revenue for the government through taxes and duties, supporting public finances. The company’s investments in infrastructure and technology drive economic activity. These investments also create new opportunities for local businesses.
Marksans Pharma’s impact is also evident in its corporate social responsibility (CSR) initiatives. The company undertakes various projects aimed at improving the quality of life in the communities where it operates. These projects focus on areas such as education and rural development.
The company’s strong leadership and governance structure further enhance its impact. Marksans Pharma is promoted by Mr. Mark Saldanha, who provides strategic direction and oversight. The company's management team consists of experienced professionals. They are responsible for driving its growth and fostering innovation. This leadership ensures that Marksans Pharma remains focused on its goals and continues to deliver value to its stakeholders.
Marksans Pharma’s impact is also reflected in its ability to adapt to changing market dynamics. The company regularly reviews and updates its strategies. This ensures it stays competitive and can meet the evolving needs of its customers. This proactive approach allows Marksans Pharma to navigate challenges effectively. It also positions the company to seize opportunities in the ever-evolving pharmaceutical industry.
Marksans Pharma Limited has made a significant impact on the pharmaceutical industry through its commitment to quality and accessibility. With a focus on continuous improvement, Marksans Pharma is well-positioned for future growth. The company aims to maintain its positive impact in the pharmaceutical industry.
Marksans Pharma operates in the pharmaceutical sector. Its primary focus is on the healthcare and life sciences industry. The company has been in business since 2000, giving it over two decades of experience in the pharmaceutical field. Its extensive experience has helped the company build a strong presence in domestic markets. Additionally, it has expanded its reach to international markets as well.
The headquarters of Marksans Pharma is located in Mumbai, Maharashtra. This strategic location enhances the company’s operations by providing logistical advantages. It also facilitates easy access to both national and global markets. Mr. Mark Saldanha promotes the company with 43.80% stakes. He plays a crucial role in its strategic direction and growth. A team of professional promoters manages the operations of the company-
- Mark Saldanha
- Sandra Saldanha
- Varddhman V Jain
- Sunny Sharma
- Seetharama R Buddharaju
Marksans Pharma plays a significant role in the pharmaceutical sector. However, it is not the largest company in terms of market share or market capitalization. Yet, the company has carved out a niche by focusing on quality and innovation. The promoter shareholding in Marksans Pharma is significant, with Mr Mark Saldanha holding a notable stake. This ensures strong governance and strategic oversight for the company.
The registered office and registrar’s office of Marksans Pharma is in Mumbai, Maharashtra. Marksans Pharma Limited is a well-established pharmaceutical company. It is recognized for its diverse product range and unwavering commitment to quality. With strong promoter backing, Marksans Pharma continues to be a key player in the healthcare industry. Its strategic focus on innovation further strengthens its position in the market.
Impact of Marksans Pharma
Marksans Pharma Limited has made a significant impact on the pharmaceutical industry, both in India and globally. The company’s focus on quality and accessibility has enabled it to provide essential medications to millions of people. This impact is evident in various aspects of its operations and contributions to healthcare.Marksans Pharma’s commitment to quality is one of its most notable impacts. The company ensures that all its products meet stringent international standards. This dedication to quality has earned it certifications from various global regulatory bodies. These include the US FDA, UK MHRA, and Australian TGA.
Innovation is another area where Marksans Pharma has made a significant impact. The company invests heavily in research and development to create improved pharmaceutical formulations. This focus on innovation has led to the development of advanced drug delivery systems and solutions.
The company’s impact extends to its role in making medications more accessible. Marksans Pharma produces a wide range of generic drugs, which are more affordable than their branded counterparts. This affordability makes essential medications accessible to a larger population, particularly in developing countries with limited healthcare resources. Marksans Pharma’s efforts in this area contribute to improving public health and reducing the burden of disease.
The economic impact of Marksans Pharma is also significant. The company employs thousands of people, contributing to economic growth and development. Marksans Pharma’s operations generate revenue for the government through taxes and duties, supporting public finances. The company’s investments in infrastructure and technology drive economic activity. These investments also create new opportunities for local businesses.
Marksans Pharma’s impact is also evident in its corporate social responsibility (CSR) initiatives. The company undertakes various projects aimed at improving the quality of life in the communities where it operates. These projects focus on areas such as education and rural development.
The company’s strong leadership and governance structure further enhance its impact. Marksans Pharma is promoted by Mr. Mark Saldanha, who provides strategic direction and oversight. The company's management team consists of experienced professionals. They are responsible for driving its growth and fostering innovation. This leadership ensures that Marksans Pharma remains focused on its goals and continues to deliver value to its stakeholders.
Marksans Pharma’s impact is also reflected in its ability to adapt to changing market dynamics. The company regularly reviews and updates its strategies. This ensures it stays competitive and can meet the evolving needs of its customers. This proactive approach allows Marksans Pharma to navigate challenges effectively. It also positions the company to seize opportunities in the ever-evolving pharmaceutical industry.
Marksans Pharma Limited has made a significant impact on the pharmaceutical industry through its commitment to quality and accessibility. With a focus on continuous improvement, Marksans Pharma is well-positioned for future growth. The company aims to maintain its positive impact in the pharmaceutical industry.
FAQ’s
What is the share price of Marksans Pharma Ltd today?
Marksans Pharma Ltd share price as on 20 Dec 2025 is ₹ 184.38
What is the Market Cap of Marksans Pharma Ltd?
The market cap of Marksans Pharma Ltd stock is ₹8,226.73 Cr.
What is the PE Ratio of Marksans Pharma Ltd?
The Price to Earnings (P/E) Ratio of Marksans Pharma Ltd is 53.58
What is the PB Ratio of Marksans Pharma Ltd?
The Price to Book (P/B) Ratio of Marksans Pharma Ltd is 7.28
What is the 52 week high of Marksans Pharma Ltd Share Price?
The 52 week high of Marksans Pharma Ltd share price stands at ₹332.40
What is the 52 week low of Marksans Pharma Ltd Share Price?
The 52 week low of Marksans Pharma Ltd share price stands at ₹162
How can I buy shares of Marksans Pharma Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Marksans Pharma Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
